Developing safer drugs to target cancer by inhibiting Hsp90
Official title: Engineering the Next Generation of Safer Hsp90 Inhibitors
Funded at University of Notre Dame · NIH-11009070 · Data updated 2026-11-12
This study is working on new treatments for cancer by finding ways to block a protein called Hsp90 that helps cancer cells grow, with the hope of making these treatments safer and more effective for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Notre Dame NIH-funded |
| Lab location | 1 site (Notre Dame, United States) |
| Project start | March 1, 2023 |
| Project end | December 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $453,814 |
| NIH project number | 5R01CA270147-03 |
| Project ID | NIH-11009070 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with various types of cancer who may benefit from new treatment options.
✕Less likely to help
Patients who are not currently undergoing cancer treatment or those with non-cancerous conditions may not receive any benefit from this research.
What this research studies
This research focuses on creating new inhibitors for a protein called Hsp90, which plays a crucial role in cancer cell growth. By targeting Hsp90, the goal is to disrupt multiple cancer signaling pathways simultaneously, potentially leading to more effective cancer treatments. The researchers aim to optimize these inhibitors to avoid the toxic side effects seen in previous treatments, ensuring they do not increase Hsp90 levels in patients. The project includes preclinical studies to evaluate the best candidates for future clinical trials.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective cancer therapies that minimize side effects for patients.
How similar studies have gone: Previous research has shown promise in targeting Hsp90, but this approach aims to improve upon earlier methods that faced significant challenges.
Where this research is happening
-
University of Notre Dame
Notre Dame, United States Active
Researchers
- Principal investigator: Blagg, Brian S J — University of Notre Dame
- Study coordinator: Blagg, Brian S J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.